138490-96-7

Basic information

• Product Name: 3,4-diMethoxy-2-(trifluoroMethyl)benzaldehyde
• Synonyms: 3,4-diMethoxy-2-(trifluoroMethyl)benzaldehyde
• CAS NO: 138490-96-7
• Molecular Formula: C₁₀H₉F₃O₃
• Molecular Weight: 234.1718696
• Mol File: 138490-96-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 301.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.282±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3,4-diMethoxy-2-(trifluoroMethyl)benzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-diMethoxy-2-(trifluoroMethyl)benzaldehyde(138490-96-7)
• EPA Substance Registry System: 3,4-diMethoxy-2-(trifluoroMethyl)benzaldehyde(138490-96-7)

Safety Data

• Hazardous Substances Data: 138490-96-7(Hazardous Substances Data)

Upstream product

• 138490-95-6 2-iodo-3,4-dimethoxybenzaldehyde 
• 2923-18-4 sodium 2,2,2-trifluoroacetate 
• 621-59-0 isovanillin 
• 138490-94-5 2-iodoisovanillin 

Downstream Products

• 634924-70-2 (1S)-3,4-dimethoxy-2-tifluoromethyl-1-((trimethylsilyl)oxy)phenylacetonitrile 
• 634924-74-6 (S)-1-(3,4-dimethoxy-2-trifluoromethylphenyl)-2-methylaminoethanol 
• 634924-75-7 (R)-1-(3,4-dimethoxy-2-trifluoromethylphenyl)-2-methylaminoethanol 
• 634924-76-8 1-N-[2-(3,4-dimethoxy-2-trifluoromethylphenyl)-2-hydroxyethyl]formamide 
• 634924-77-9 1-N-[2-(3,4-dimethoxy-2-trifluoromethylphenyl)-2-hydroxyethyl]formamide 
• 1338709-29-7 C₁₀H₉F₃O₄ 
• 138490-92-3 5-Trifluoromethyl-TMQ hydrochloride 
• 138491-07-3 3,4-bis(benzyloxy)-2-(trifluoromethyl)benzyl cyanide 
• 138491-00-6 3,4-dimethoxy-2-(trifluoromethyl)benzyl cyanide 
• 138491-04-0 3,4-dihydroxy-2-(trifluoromethyl)benzyl cyanide 
• 138491-36-8 3,4-dimethoxy-2-(trifluoromethyl)benzyl bromide 
• 138491-10-8 N-<2-<3,4-bis(benzyloxy)-2-(trifluoromethyl)phenyl>ethyl>-3',4',5'-trimethoxyphenylacetamide 
• 132335-31-0 6,7-Bis-benzyloxy-5-trifluoromethyl-1-(3,4,5-trimethoxy-benzyl)-3,4-dihydro-isoquinoline 
• 138491-15-3 6,7-bis(benzyloxy)-1-(3',4',5'-trimethoxybenzyl)-5-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

Asymmetric synthesis of (R)- and (S)-2-trifluoromethylepinephrine

An asymmetric synthesis of (R)- and (S)-2-trifluoromethylepinephrine (1R and 1S) is presented. Trifluoromethylation involves nucleophilic aromatic substitution of halobenzene 4 most likely via a copper mediated CF3 anion equivalent generated in

Synthesis of halogenated trimetoquinol derivatives and evaluation of their β-agonist and thromboxane A2 (TXA2) antagonist activities

The 5,8-difluoro (4), 5-iodo (5), 8-iodo (6), and 5-trifluoromethyl (7) derivatives of trimetoquinol (TMQ, 1) have been synthesized and evaluated for their ability to stimulate β1 (guinea pig atria) and β2 (guinea pig trachea) adrenoceptors as well as for their inhibitory activity against U46619 [a thromboxane A2 (TXA2) mimetic]-mediated contraction of rat thoracic aorta and human platelet aggregation. Both 5 and 6 were considerably less active than TMQ on both β-adrenergic systems and gave a rank order of stimulatory potency of 1 >> 6 ≥ 5. Similarly, iodine substitution at either position also caused a reduction in TXA2 antagonist activity with a rank order potency of 1 > 6 >> 5. Compared to 1, however, 5-iodo-TMQ (5) showed a marked selectivity for blockade of U46619 responses in rat aorta over human platelets. On β-systems, 4 had reduced potency compared to TMQ and was similarly nonselective. Introduction of a trifluoromethyl group at the 5- position of TMQ completely abolished both β1- and β2-adrenergic agonist activities while imparting weak antagonist activity on β1 receptors. On TXA2 systems, both 4 and 7 possessed significantly decreased inhibitory activity compared to TMQ. The synthetic approaches to the synthesis of 8- (trifluoromethyl)-TMQ (8) are also described. The enantiomers of the 8-fluoro derivative (3) of TMQ were separated on a preparative Chiralcel OD column and evaluated on β-adrenergic systems and TXA2 systems. On β-adrenergic systems, (S)-(+)-8-fluoro-TMQ was at least 10-fold more potent than (R)-(-)- 8-fluoro-TMQ. Conversely, (R)-(-)-8-fluoro-TMQ was approximately 14-fold more potent as an antagonist of TXA2-mediated aggregation in human platelets than (S)-(+)-8-fluoro-TMQ. In contrast to platelets, (S)-(+)-8-fluoro-TMQ was an agonist in rat aorta whereas (R)-(-)-8-fluoro-TMQ was an antagonist.